Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MediciNova has completed enrollment in its Phase II trial (MN-221-CL-007) evaluating the safety and efficacy of MN-221 for treatment of acute exacerbations of asthma.
Subscribe to our email newsletter
The randomized, double-blind trial enrolled a total of 176 asthma patients in the emergency room not responding to standard pharmacotherapy.
The primary efficacy endpoint of the placebo-controlled study is the improvement in FEV1.
The secondary endpoints such as reduction in hospital admissions and various clinical significances will be examined.
The company plans to release preliminary results of the study in the second quarter of 2012.
MediciNova president and chief executive officer Yuichi Iwaki said the completion of enrollment keeps the company on track for planning the further development of MN-221 in the treatment of acute asthma exacerbations.